PSMA-Targeted Radioligand Therapy: From Evidence to Clinical Implementation

Organized by : Novartis

Synopsis : The treatment paradigm for advanced prostate cancer is rapidly evolving, with PSMA‑targeted radioligand therapy (RLT) moving earlier in the disease continuum and beyond a last‑line option. As precision medicine becomes central to care, urologists are playing an increasingly critical role in identifying the right patients, initiating timely discussions on RLT, and driving multidisciplinary decision‑making. This masterclass will explore emerging evidence supporting earlier‑line RLT, practical patient selection, and real‑world integration of theranostics into urology‑led prostate cancer care through expert insights and interactive case discussions.

Target Audience : Urologists managing/ co-managing advanced and metastatic prostate cancer

Learning outcomes :

• A clear understanding of the evolving role of PSMA‑targeted RLT and its move into earlier treatment lines
• Practical guidance on when and which patients to consider for RLT, including pre‑chemotherapy settings
• Navigate the end‑to‑end multidisciplinary journey of an mPC patient receiving Lu‑PSMA‑RLT, from referral to follow‑up
• Best‑practice approaches for patient referral,treatment monitoring, and post‑RLT follow‑up